

# Direct use of eazyplex<sup>®</sup> SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in *Escherichia coli* and *Klebsiella pneumoniae* bloodstream infections

Barbara Fiori<sup>1-3,\*</sup>Tiziana D'Inzeo<sup>2,3,\*</sup>Brunella Posteraro<sup>4,5</sup>Giulia Menchinelli<sup>3</sup>Flora Marzia Liotti<sup>3</sup>Giulia De Angelis<sup>2,3</sup>Flavio De Maio<sup>3</sup>Massimo Fantoni<sup>6,7</sup>Rita Murri<sup>6,7</sup>Giancarlo Scoppettuolo<sup>6</sup>Giulio Ventura<sup>6</sup>Mario Tumbarello<sup>6,7</sup>Francesco Pennestri<sup>4</sup>Francesco Taccari<sup>7</sup>Maurizio Sanguinetti<sup>2,3</sup>Teresa Spanu<sup>2,3</sup>

<sup>1</sup>Scuola Provinciale Superiore di Sanità Claudiana, Bolzano, Italy; <sup>2</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze di Laboratorio e Infettivologiche, Rome, Italy; <sup>3</sup>Università Cattolica del Sacro Cuore, Istituto di Microbiologia, Rome, Italy; <sup>4</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Gastroenterologiche, Endocrino-Metaboliche e Nefro-Urologiche, Rome, Italy; <sup>5</sup>Università Cattolica del Sacro Cuore Rome, Istituto di Patologia e Semeiotica Medica, Rome, Italy; <sup>6</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Malattie Infettive, Rome, Italy; <sup>7</sup>Istituto di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy

\*These authors contributed equally to this work

Correspondence: Maurizio Sanguinetti  
Institute of Microbiology, Fondazione  
Policlinico A. Gemelli IRCCS, Largo  
Agostino Gemelli 8, Rome 00168, Italy  
Tel +396 305 4411  
Fax +396 305 1152  
Email maurizio.sanguinetti@unicatt.it

This article was published in the following Dove Press journal:  
*Infection and Drug Resistance*

**Objectives:** To describe a rapid workflow based on the direct detection of *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kp*) producing CTX-M extended-spectrum  $\beta$ -lactamase (ESBL) and/or carbapenemases (eg, KPC, VIM) from blood cultures (BCs) and the infectious disease (ID) consulting for timely appropriate antimicrobial therapy.

**Methods:** This observational, retrospective study included adult patients with a first episode of *Ec* or *Kp* bloodstream infection (BSI) in a large Italian university hospital, where an inpatient ID consultation team (IDCT) has been operational. Results from the BCs tested for detecting *bla*<sub>CTX-M</sub>, *bla*<sub>KPC</sub>, *bla*<sub>NDM</sub>, *bla*<sub>OXA-48-like</sub>, and *bla*<sub>VIM</sub> genes by the eazyplex<sup>®</sup> SuperBug CRE assay in *Ec* and *Kp* organisms had been notified for antimicrobial therapy consulting.

**Results:** In 321 BSI episodes studied, we found that 151 (47.0%) of *Ec* or *Kp* organisms harbored *bla*<sub>CTX-M</sub> and/or *bla*<sub>KPC</sub> and/or *bla*<sub>VIM</sub> (meantime from BC collection: 18.5 h). Empirical antimicrobial treatment was appropriate in 21.8% (33/151) of BSIs, namely 5.9% (3/51) of BSIs caused by KPC/VIM producers and 30.0% (30/100) of BSIs caused by CTX-M producers. After notification of results, the IDCT modified antimicrobial therapy (mean time from BC collection: 20 h) such that the proportion of appropriate treatments increased to 84.8% (128/151) of BSIs, namely 70.6% (36/51) of BSIs caused by KPC/VIM producers and 92.0% (92/100) of BSIs caused by CTX-M producers.

**Conclusion:** Our study shows that a rapid diagnostic-driven clinical strategy allowed for early prescription of potentially effective antimicrobial therapy in BSIs caused by CTX-M ESBL- and/or KPC/VIM carbapenemase-producing *Ec* and *Kp* organisms.

**Keywords:** *Escherichia coli*, *Klebsiella pneumoniae*, bloodstream infection, drug resistance, targeted therapy, infectious disease consultation

## Background

*Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kp*) are the leading causes of bloodstream infections (BSIs) involving gram-negative bacteria, and  $\beta$ -lactams are among the most used drugs for treatment of such infections. Globally, increasing attention is being focused on the growing involvement of extended-spectrum- $\beta$ -lactamase (ESBL)-producing isolates of *Ec* and *Kp* in serious BSIs.<sup>1,2</sup> This trend is

due largely to the emergence of CTX-M ESBLs, a rapidly expanding group of enzymes that are being encountered with increasing frequency in both bacterial species.<sup>3,4</sup> Carbapenems represent one therapeutic option for infections caused by multidrug-resistant (MDR) ESBL-producing organisms; however, resistance to this class of antibiotics has increased during the last decade.<sup>5</sup> Carbapenem-resistant *Enterobacteriaceae*, particularly *Kp* producing *bla*<sub>KPC</sub>, are now responsible for a new dramatic scenario and are emerging as a relevant cause of health care-associated BSIs in several countries, including Italy.<sup>6–8</sup>


Detecting rapidly and accurately BSI pathogens is a critical factor for earlier implementation of effective treatment of these life-threatening infections. Although blood culture (BC) remains the gold standard for diagnosing BSIs, the time-consuming process of isolate identification/characterization with conventional culture-based methods has been improved by the development of faster technologies, allowing identification of the infecting pathogen directly from BC bottles.<sup>9</sup> In addition to matrix-assisted laser desorption ionization–time of flight mass spectrometry (eg, MALDI BioTyper™ system [Bruker Daltonics, Bremen, Germany]), various commercial BC-based nucleic acid assays can shorten the identification time of pathogens and/or resistance genes,<sup>10</sup> and have added value for antibiotic stewardship decisions by decreasing the time to initiating appropriate antibiotic therapy.<sup>11–15</sup>

To provide rapid pathogens' characterization for early appropriate treatment of patients with *Ec*- or *Kp*-BSI hospitalized in a CTX-M and KPC-endemic setting, we implemented the laboratory's BC workflow that uses the eazyplex® SuperBug CRE assay (Amplex Diagnostics GmbH, Biolife italiana SRL, Milan, Italy) when *Ec* or *Kp* organisms were identified by direct MALDI BioTyper™ analysis from positive BCs.<sup>10</sup> Clinical experience to date shows that this panel identifies the CTX-M-1-group and CTX-M-9-group ESBLs and the VIM (–1 to –37), NDM (–1 to –7), KPC (–2 to –15), and OXA-48-like (–48, –162, –204, and –244) carbapenemases with high accuracy when applied directly to both cultured bacterial and urine samples.<sup>16–18</sup> Our workflow was integrated with real-time result notification and inpatient infectious disease consultation team (IDCT) intervention. In the present one-year retrospective study, we assessed whether this laboratory/clinical workflow may have affected the timely prescription of appropriate antimicrobial therapy for BSIs caused by CTX-M ESBL- and/or carbapenemase-producing *Ec* or *Kp* organisms.

## Methods

This study was conducted from 15 January 2015 through 15 January 2016 at a 1,200-bed university hospital (Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy), under approval by our institutional Ethics Committee (no. 0040288/16). A central microbiology laboratory, which is open from 7:00 a.m. to 7:00 p.m., Monday through Friday and from 7:00 a.m. to 4:00 p.m., Saturday serves all the hospital wards. The hospital has an IDCT comprising four ID specialists, who operate on a request basis (via the hospital's computerized information system) by the physicians operating in medical and surgical wards (except for hematology unit and ICU, which have dedicated ID specialists). The IDCT takes charge of patients at the bedside within 24 hrs of the request.<sup>19</sup> Eligible patients were adults (≥18 years old) with a first, clinically significant episode of BC-documented BSI for *Ec* or *Kp*. Patients were excluded if they died or were discharged before BC results were available, or if they had incomplete data.

Figure 1 depicts the diagnostic workflow used in this study. When patients' BC signaled positive in either BACT/ALERT® VIRTUO™ (bioMérieux, Marcy l'Étoile, France) or BACTEC™ FX (Becton Dickinson, Sparks, MD, USA) automated systems, aliquots from BC bottle broths were subjected to the direct MALDI BioTyper™ analysis<sup>10</sup> and, when *Ec* or *Kp* organisms were identified, the eazyplex® SuperBug CRE assay was performed. MALDI BioTyper™ identifications of *Ec* or *Kp* organisms were always concordant with those of reference (culture-based) identification methods (Figure 1). As described elsewhere,<sup>17</sup> the eazyplex® SuperBug CRE assay relies on a loop-mediated isothermal amplification (that covers the aforementioned carbapenemase variants) and a subsequent real-time fluorescence based visualization of the amplification products. For each patient, results of the laboratory procedure were immediately available to the IDCT. The microbiologist also informed the in-charge ID specialist about that identified organisms could harbor *bla* genes other than those detected in the eazyplex® SuperBug CRE assay (eg, TEM/SHV ESBLs, plasmidic AmpC β-lactamases), which confer non-susceptibility to extended-spectrum cephalosporins (ESC) or carbapenems (carba). Antimicrobial minimum inhibitory concentrations (MICs) of the *Ec* or *Kp* isolates identified by the MALDI BioTyper™ analysis were determined by antimicrobial susceptibility testing (AST) broth microdilution methods and interpreted according to the European Committee on Antimicrobial



**Figure 1** Diagnostic workflow using MALDI BioTyper™ analysis/eazyplex® SuperBug CRE assay (direct procedure) or culture-based methods (reference procedure) on positive blood cultures from *E. coli* or *K. pneumoniae* bloodstream infections (BSIs). Results from both the diagnostic procedures were notified to an IDCT for streamlining the antimicrobial treatments of BSIs.

**Abbreviations:** ID, identification; IDCT, infectious disease consultation team.

Susceptibility Testing (EUCAST) breakpoints (version 8.0, [http://www.eucast.org/clinical\\_breakpoints/](http://www.eucast.org/clinical_breakpoints/)). We performed phenotypic detection of resistance mechanisms according to the EUCAST guidelines (version 2.0, [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Resistance\\_mechanisms/](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/)). To confirm antimicrobial resistance profiles, all the *Ec* and *Kp* isolates underwent PCR sequencing of the *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, *bla*<sub>CTX-M</sub>, *bla*<sub>KPC</sub>, *bla*<sub>NDM</sub>, *bla*<sub>OXA-48-like</sub>, *bla*<sub>VIM</sub>, and *bla*<sub>AmpC</sub> genes.<sup>2,20–22</sup>

## Diagnostic and clinical definitions

Time to detection of growth (TTD) was the time from when the BC bottle entered into the BC system to when it signaled positive. The time to result (TTR) was the time elapsed between the BC system entry and completion of the aforementioned direct-detection procedure. We assessed the appropriateness of antibiotic treatments at the time of BC collection (empirical therapy) and after notification of the procedure (targeted therapy) or AST (definitive therapy) results. We defined the antimicrobial treatment as appropriate when the patient received the first

(empirical) and/or subsequent (diagnostic-driven) antibiotic with known susceptibility by microbiology report.

## Results

We studied 321 patients with *Ec* (n=214) or *Kp* (n=107) BSIs. The mean TTD for the patient-unique positive BCs (n=321) was 10.3 h (range: 2–90 h). The mean TTR for the 151 (47.0%) *Ec* or *Kp* organisms harboring *bla*<sub>CTX-M</sub> and/or *bla*<sub>KPC</sub> and/or *bla*<sub>VIM</sub> (as detected by the MALDI BioTyper™ analysis and eazyplex® SuperBug CRE assay) was 18.5 h (range: 3.3–96 h). The mean AST was 51 h (range: 36–141 h) for all the 321 *Ec* and *Kp* isolates, including 106 (33.0%) isolates that were non-susceptible to ESC but susceptible to carba (ESCR-carbaS phenotype) (Table 1). Accordingly, ESBL production was detected in 36.0% (77/214) of the *Ec* isolates and in 21.5% (23/107) of the *Kp* isolates, and all the 100 isolates carried CTX-M ESBL genes. The *bla*<sub>CMY-2</sub> gene (not detectable by the eazyplex® SuperBug CRE assay) was detected in the remaining 1.8% (6/321) of *Ec* or *Kp* isolates. The proportions of the *Ec* or *Kp* isolates harboring carbapenemase genes (ESCR-carbaR phenotype) were 0.9% (2/214) and 45.8% (49/107),

**Table 1** Antimicrobial susceptibilities for 321 *Escherichia coli* and *Klebsiella pneumoniae* BSI organisms (151 positive and 170 negative by the eazylex® SuperBug CRE assay detection) according to the presence of resistance genes

Type of $\beta$ -lactamase in the indicated species (no. of isolates) <sup>a</sup>	No. (%) of isolates susceptible to the following antimicrobial agents											
	CTX	CAZ	FEP	ETP	MEM	TZP	AK	GM	CIP	SXT	TGC	CST
<i>E. coli</i> (214)												
<i>bla</i> <sub>CTX-M</sub> (77)	0 (0.0)	5 (6.5)	0 (0.0)	77 (100)	77 (100)	53 (68.8)	51 (66.2)	47 (61)	6 (7.8)	38 (49.3)	—	—
<i>bla</i> <sub>CMY</sub> (5) <sup>b</sup>	0 (0.0)	0 (0.0)	5 (100)	5 (100)	5 (100)	1 (20.0)	4 (80.0)	3 (60.0)	1 (20.0)	1 (20.0)	—	—
<i>bla</i> <sub>KPC</sub> / <i>bla</i> <sub>VIM</sub> (2)	0	0	0	0	0	0	1	1	0	1	2	2
None (130)	130 (100)	130 (100)	130 (100)	130 (100)	130 (100)	114 (87.7)	129 (99.2)	113 (86.9)	95 (73.1)	83 (63.8)	—	—
<i>K. pneumoniae</i> (107)												
<i>bla</i> <sub>CTX-M</sub> (23)	0 (0.0)	0 (0.0)	0 (0.0)	23 (100)	23 (100)	6 (26.1)	17 (73.9)	6 (26.1)	2 (8.7)	3 (13.0)	—	—
<i>bla</i> <sub>CMY</sub> (1) <sup>b</sup>	1	1	1	0	0	0	1	1	1	1	—	—
<i>bla</i> <sub>KPC</sub> / <i>bla</i> <sub>VIM</sub> (49)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	12 (24.5)	41 (83.7)	2 (4.0)	9 (18.4)	39 (78.6)	29 (59.2)
None (34)	34 (100)	34 (100)	34 (100)	34 (100)	34 (100)	30 (88.2)	34 (100)	34 (100)	30 (88.2)	31 (91.2)	—	—

**Notes:** Colistin and tigecycline susceptibility results were available only for carbapenem-resistant isolates. We did not calculate percentages in cases with less than five isolates. <sup>a</sup>We identified the extended-spectrum  $\beta$ -lactamase (ESBL), plasmidic AmpC  $\beta$ -lactamase, and carbapenemase genes by standard PCR sequencing analysis. Specifically, *E. coli* isolates harbored *bla*<sub>CTX-M-15</sub> (n=55), *bla*<sub>CTX-M-14</sub> (n=9), *bla*<sub>CTX-M-27</sub> (n=13), *bla*<sub>CMY-2</sub> (n=5), *bla*<sub>KPC-3</sub> (n=1), and *bla*<sub>VIM-1</sub> (n=1); *K. pneumoniae* isolates harbored *bla*<sub>CTX-M-15</sub> (n=23), *bla*<sub>CMY-2</sub> (n=1), *bla*<sub>KPC-2</sub> (n=2), *bla*<sub>CTX-M-15</sub>+*bla*<sub>KPC-3</sub> (n=4), *bla*<sub>KPC-3</sub> (n=41), and *bla*<sub>KPC-3</sub>+*bla*<sub>VIM-1</sub> (n=2). None refers to the isolates not harboring such genes. <sup>b</sup>Six isolates harboring *bla*<sub>CMY</sub> genes had a negative result with the eazylex® SuperBug CRE assay.

**Abbreviations:** CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ETP, ertapenem; MEM, meropenem; TZP, piperacillin-tazobactam; AK, amikacin; GM, gentamicin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline; CST, colistin.

respectively, with *bla*<sub>KPC-3</sub> being the most commonly detected gene (Table 1).

Within few hours after BCs were drawn, physicians started empirical antimicrobial therapy in all the 321 patients. The antibiotics most frequently used were piperacillin-tazobactam (24.3%) and fluoroquinolones (23.7%) followed by carba (16.2%) and ESC (8.7%); when combination therapy was used, piperacillin-tazobactam plus amikacin (9.3%) was the most frequent antibiotic regimen. In most cases (85.0%), the physician in charge of the patient made the choice of the empirical treatment, and did not use a predefined protocol. As shown in Table 2, empirical antimicrobial therapy was appropriate in 41.1% (132/321) of BSIs, with 5.9% (3/51) for KPC/VIM BSIs and 30.0% (30/100) for CTX-M BSIs (Figure 2).

After notification of results from both the MALDI BioTyper™ analysis and eazypex® SuperBug CRE assay, the IDCT specialists recommended a modification of the empirical antimicrobial therapy (Table 2). These actions increased the proportion of appropriate antimicrobial therapy to 89.1% (286/321), with 92.0% (92/100) for CTX-M BSIs and 70.6% (36/51) for KPC/VIM BSIs (Figure 2). The

remaining 35 patients, 15 and 8 of whom were infected by carbapenemase- or CTX-M-producing *Ec* or *Kp* organisms, respectively, received antimicrobial treatments that were different from the previous empirical treatments, but the selected drug(s) were still inactive (as later documented by AST on the relative isolates). The drugs were meropenem plus colistin in 15 patients (all infected with colistin-resistant KPC-producing *Kp* isolates), piperacillin-tazobactam in 15 patients (8 with non-CTX M ESBL-producing isolates, 6 with ESCS-CarbaS isolates, and 1 with CMY-producing isolates), and fluoroquinolones in 5 patients.

Following release of AST results, antimicrobial therapies were further modified in the 35 aforementioned patients (Table 2), leading to a proportion of appropriate treatments up to 99.7% (320/321 patients) (Figure 2). One patient never received effective therapy, as the infecting *Kp* isolate was resistant to all the antibiotics tested (Table 1).

## Discussion

To the best of our knowledge, this study is the first large hospital-based report that has evaluated the effects of the rapid detection of *Ec* and *Kp* isolates producing *bla*<sub>CTX-M</sub> or


**Table 2** Appropriate empirical or diagnostic-driven antimicrobial treatments stratified by the type of organisms causing bloodstream infections in 321 patients

	No. (%) of appropriate empirical treatments	No. (%) of modifications leading to appropriate treatments, according to the results by	
		MALDI BioTyper™ analysis plus eazypex® SuperBug CRE assay	Antimicrobial susceptibility testing
Organisms causing BSI			
KPC/VIM-producing <i>E. coli</i> (n=2)	0/2 (0.0)	2/2 (100)	0/2 (0.0)
CTX-M-producing <i>E. coli</i> (n=77)	22/77 (28.6)	48/77 (62.3)	7/77 (9.1)
CMY-producing <i>E. coli</i> (n=5)	1/5 (20.0)	3/5 (60.0)	1/5 (20.0)
ESCS-carbaS <i>E. coli</i> (n=130)	77/130 (59.2)	44/130 (33.8)	9/130 (6.9)
KPC/VIM-producing <i>K. pneumoniae</i> (n=49)	3/49 (6.1)	31/49 (63.3)	14/49 (28.6) <sup>a</sup>
CTX-M-producing <i>K. pneumoniae</i> (n=23)	8/23 (34.8)	14/23 (60.9)	1/23 (4.3)
CMY-producing <i>K. pneumoniae</i> (n=1)	1/1 (100)	0/1 (0.0)	0/1 (0.0)
ESCS-carbaS <i>K. pneumoniae</i> (n=34)	20/34 (58.8)	12/34 (35.3)	2/34 (5.9)
Total organisms (n=321)	132/321 (41.1)	154/321 (48.0)	34/321 (10.6) <sup>a</sup>

**Notes:** <sup>a</sup>The treatment was not appropriate in 1 (0.3%) of 321 BSIs because the infecting KPC/VIM-producing *K. pneumoniae* organism had an AST-determined pandrug resistance phenotype.

**Abbreviations:** CRE, carbapenemase-resistant *Enterobacteriaceae*; BSI, bloodstream infection; ESCS-carbaS, extended-spectrum cephalosporin susceptible-carbapenem susceptible.





**Figure 2** Appropriateness of antimicrobial treatments in subgroups defined by the presence of the indicated resistance determinants in 321 patients with *Ec* or *Kp* bloodstream infections. Empirical or targeted antimicrobial therapy was the administration of antibiotics before and after the eazyplex<sup>®</sup> SuperBug CRE assay results were available, respectively. Definitive antimicrobial therapy was the administration of antibiotics after the antimicrobial susceptibility testing results were available. Overall, antimicrobial therapy was appropriate for any antibiotic with known susceptibility by microbiology report.

*bla*<sub>KPC</sub> or *bla*<sub>VIM</sub> on the timing of appropriate antimicrobial therapy. Several recent studies have performed similar evaluations,<sup>11,12,23,24</sup> but all have involved a small number of patients with CTX-M- and carbaR-BSI, and none of these studies used the eazyplex<sup>®</sup> SuperBug CRE assay as a rapid resistance detection method. Here, integrating this assay with MALDI BioTyper<sup>™</sup> analysis, our diagnostic algorithm allowed the successful identification of all *Ec* and *Kp* producing *bla*<sub>CTX-M</sub>, and/or *bla*<sub>KPC</sub> and/or *bla*<sub>VIM</sub>, and, more importantly, the antimicrobial streamlining in the course of BSI. Therefore, this study has some strengths. First, the results by the proposed laboratory workflow are obtainable in a mean time of 18 h, which may help clinicians to provide more therapy that is effective during the early period of clinical illness and may facilitate rapid decisions regarding isolating patients to prevent transmission. Second, the procedure underlying this workflow is simple and easy to perform and requires minimal training. Third, rapidly detecting a specific type of carbapenemase is particularly important because of the introduction of new antibiotics potentially active against certain carbapenemases into the clinical practice. In this context, our workflow is undoubtedly a positive contribution to infection control/effective treatment of patients.

Prior to the implementation of the rapid BC strategy in our hospital, we noted significant delays in initiating effective antimicrobial therapy.<sup>2,25</sup> Conversely, based on the strategy shown here, the IDCT specialists switched 64.7% of patients with KPC/VIM BSI and 62.0% of patients with

CTX-M BSI from inappropriate empirical antimicrobial regimen to effective coverage within a mean time of 20 h. In the remaining 23 patients on inappropriate empirical therapy, 15 of whom were infected by KPC producers and eight by CTX-M producers, the original regimen was discontinued, but each patient was treated with a drug against which his/her isolate had displayed resistance in AST testing. All 15 patients with KPC BSI that maintained an ineffective coverage received a colistin-based regimen. A problem of considerable importance is the increasing rate of colistin-resistance among KPC-producing *Kp* isolates because of its shortage of therapeutic options in patients with BSIs.<sup>26</sup> There is an endemic widespread of such isolates in Italian healthcare facilities,<sup>27,28</sup> and it was approximately 40% in our hospital.

The ineffective drug was piperacillin-tazobactam in all but one patients infected by CTX-M producers. Carbapenems seem to be a suitable option for treating severe infections due to those organisms; however, their increased use exerts selection pressure for carbapenem resistance. Therefore, experts have suggested carbapenem-sparing antibiotic regimens, particularly in settings such as ours where carbapenem-resistant isolates are common. Although there is emerging evidence that piperacillin-tazobactam may be a good choice for treating ESBL BSIs, its role is still controversial, particularly for BSIs from non-urinary sources.<sup>29–33</sup> Additionally, the susceptibility of ESBL producers to piperacillin-tazobactam is less predictable than their susceptibility to carbapenems.<sup>2,4,20</sup>

Among our isolates, rates of resistance ranged from 31.2% of CTX-M-producing *Ec* isolates to 73.9% of CTX-M-producing *Kp* isolates. Therefore, physicians need to base their decisions regarding the empirical use of this antibiotic, until susceptibility results are available, on a sound knowledge of the local susceptibility patterns and the patient's clinical condition.

This study has some well-acknowledged limitations. First, as we conducted our analysis in a single center, the results are not necessarily applicable to other hospitals, particularly those with very low rates of *Enterobacteriaceae* infections caused by CTX-M and/or carbapenemase producers. Second, the eazypex<sup>®</sup> SuperBug CRE assay's main weakness is its inability to identify ESBLs other than CTX-M, plasmidic AmpC, and some OXA-48-like enzymes, which are found among currently spreading MDR members of *Enterobacteriaceae*.<sup>4,28</sup> Therefore, without the ability to detect these resistance determinants, the assay would miss a significant proportion of resistant isolates if implemented in settings where isolates harboring those genes occur.

## Conclusion

Our combined use of the MALDI BioTyper<sup>™</sup> analysis and eazypex<sup>®</sup> SuperBug CRE assay can be a reliable, timesaving alternative to the conventional laboratory diagnosis of BSIs caused by *Ec* or *Kp* organisms with MDR determinants (ie, CTX-M ESBLs and carbapenemases). Importantly, this rapid diagnosis can enable physicians to begin appropriate antimicrobial therapy precociously. However, the applicability of our diagnostic workflow does depend on the conditions dictated by aforementioned limitations, as well as further larger studies are necessary to validate and confirm the present findings.

## Acknowledgments

The authors would like to thank Maria Federica Ventriglia for her technical assistance. We also thanks all the ID consultants not included in the panel of Authors. The Italian Ministry for the University and Scientific Research in part supported the study by providing grants to T. S. and M. S. (Fondi Ateneo Linea D1 2014–2015).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing *Enterobacteriaceae* in Europe. *Euro Surveill*. 2008;13(47):e19044.
2. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing *Enterobacteriaceae*: importance of inadequate initial antimicrobial treatment. *Antimicrob Agents Chemother*. 2007;51(6):1987–1994. doi:10.1128/AAC.01509-06
3. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactams. *Clin Microbiol Infect*. 2008;14(Suppl 1):33–41. doi:10.1111/j.1469-0691.2007.01863.x
4. Castanheira M, Mendes RE, Jones RN, Sader HS. Changes in the frequencies of  $\beta$ -lactamase genes among *Enterobacteriaceae* isolates in U.S. hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against  $\beta$ -lactamase-producing isolates. *Antimicrob Agents Chemother*. 2016;60(8):4770–4777. doi:10.1128/AAC.00540-16
5. Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*, a key pathogen set for global nosocomial dominance. *Antimicrob Agents Chemother*. 2015;59(10):5873–5884. doi:10.1128/AAC.01019-15
6. Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant *Enterobacteriaceae* (CRE) in the CRE epicenter of the United States. *Antimicrob Agents Chemother*. 2017;61:e02349–16. doi:10.1128/AAC.02349-16
7. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *Kp*: importance of combination therapy. *Clin Infect Dis*. 2012;55(7):943–950. doi:10.1093/cid/cis588
8. Pagano L, Caira M, Trecarichi EM, et al. Carbapenemase-producing *Klebsiella pneumoniae* and hematologic malignancies. *Emerg Infect Dis*. 2014;20(7):1235–1236. doi:10.3201/eid2007.130094
9. La Scola B, Raoult D, Bereswill S. Direct identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *PLoS One*. 2009;4:e8041. doi:10.1371/journal.pone.0008041
10. Fiori B, D'Inzeo T, Giaquinto A, et al. Optimized use of the MALDI BioTyper system and the Filmarray BCID panel for direct identification of microbial pathogens from positive blood cultures. *J Clin Microbiol*. 2016;54(3):576–584.
11. Bork JT, Leekha S, Heil EL, Zhao L, Badamas R, Johnson JK. Rapid testing using the verigene gram-negative blood culture nucleic acid test in combination with antimicrobial stewardship intervention against gram-negative bacteremia. *Antimicrob Agents Chemother*. 2015;59(3):1588–1595. doi:10.1128/AAC.04259-14
12. Sothoron C, Ferreira J, Guzman N, et al. A stewardship approach to optimize antimicrobial therapy through use of a rapid microarray assay on blood cultures positive for gram-negative bacteria. *J Clin Microbiol*. 2015;53(11):3627–3629. doi:10.1128/JCM.02161-15
13. Buehler SS, Madison B, Snyder SR, et al. Effectiveness of practices to increase timeliness of providing targeted therapy for inpatients with bloodstream infections: a laboratory medicine best practices systematic review and meta-analysis. *Clin Microbiol Rev*. 2016;29(1):59–103. doi:10.1128/CMR.00053-14
14. Bookstaver PB, Nimmich EB, Smith TJ 3rd, et al. Cumulative effect of an antimicrobial stewardship and rapid diagnostic testing bundle on early streamlining of antimicrobial therapy in gram-negative bloodstream infections. *Antimicrob Agents Chemother*. 2017;61:e00189–17. doi:10.1128/AAC.00189-17
15. MacVane SH, Nolte FS, Burnham C-AD. Benefits of adding a rapid PCR-based blood culture identification panel to an established antimicrobial stewardship program. *J Clin Microbiol*. 2016;54:2455–2463. doi:10.1128/JCM.00996-16

16. Findlay J, Hopkins KL, Meunier D, Woodford N. Evaluation of three commercial assays for rapid detection of genes encoding clinically relevant carbapenemases in cultured bacteria. *J Antimicrob Chemother.* 2015;70(5):1338–1342. doi:10.1093/jac/dku445
17. García-Fernández S, Morosini MI, Marco F, et al. Evaluation of the eazyplex® SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical *Enterobacteriaceae* isolates recovered at two Spanish hospitals. *J Antimicrob Chemother.* 2015;70(4):1047–1050. doi:10.1093/jac/dku445
18. Hinić V, Ziegler J, Straub C, Goldenberger D, Frei R. Extended-spectrum  $\beta$ -lactamase (ESBL) detection directly from urine samples with the rapid isothermal amplification-based eazyplex® SuperBug CRE assay: proof of concept. *J Microbiol Methods.* 2015;119:203–205. doi:10.1016/j.mimet.2015.10.015
19. Fantoni M, Murri R, Scoppettuolo G, et al. Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? *Future Microbiol.* 2015;10(1):15–20. doi:10.2217/fmb.14.99
20. Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing *Klebsiella pneumoniae*: risk factors, molecular epidemiology, and clinical outcome. *Antimicrob Agents Chemother.* 2006;50(2):498–504. doi:10.1128/AAC.50.2.498-504.2006
21. Pagani L, Dell'Amico E, Migliavacca R, et al. Multiple CTX-M-type extended-spectrum  $\beta$ -lactamases in nosocomial isolates of *Enterobacteriaceae* from a hospital in northern Italy. *J Clin Microbiol.* 2003;41(9):4264–4269. doi:10.1128/JCM.41.9.4264-4269.2003
22. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC -lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol.* 2002;40(6):2153–2162. doi:10.1128/JCM.40.6.2153-2162.2002
23. Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction–based blood culture identification and susceptibility testing. *Clin Infect Dis.* 2015;61(7):1071–1080. doi:10.1093/cid/civ447
24. Walker T, Dumadag S, Lee CJ, et al. Clinical impact after laboratory implementation of the verigene gram-negative bacteria microarray for positive blood cultures. *J Clin Microbiol.* 2016;54(7):1789–1796. doi:10.1128/JCM.00376-16
25. Tumbarello M, Sali M, Trecarichi EM, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing *Escherichia coli*: risk factors for inadequate initial antimicrobial therapy. *Antimicrob Agents Chemother.* 2008;52(9):3244–3252. doi:10.1128/AAC.00063-08
26. Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect.* 2013;19(1):23–30. doi:10.1111/1469-0691.12070
27. Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant *Klebsiella pneumoniae*: a rapidly evolving problem in Italy, november 2013 to april 2014. *Euro Surveill.* 2014;19:e20939. doi:10.2807/1560-7917.ES2014.19.42.20939
28. Giani T, Antonelli A, Caltagirone M, et al. Evolving beta-lactamase epidemiology in *Enterobacteriaceae* from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. *Euro Surveill.* 2017;22:e30583. doi:10.2807/1560-7917.ES.2017.22.31.30583
29. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum- $\beta$ -lactamase-producing *Enterobacteriaceae*. *Antimicrob Agents Chemother.* 2016;60(7):4159–4169. doi:10.1128/AAC.00365-16
30. Ng TM, Khong WX, Harris PN, et al. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. *PLoS One.* 2016;11:e0153696. doi:10.1371/journal.pone.0153696
31. Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum  $\beta$ -lactamase bacteremia. *Clin Infect Dis.* 2015;60(9):1319–1325.
32. Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. *Infect Control Hosp Epidemiol.* 2015;36(8):981–985. doi:10.1017/ice.2015.101
33. Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with *Escherichia coli* or *Klebsiella pneumoniae* bloodstream infection and ceftriaxone resistance: a randomized clinical trial. *JAMA.* 2018;320(10):984–994. doi:10.1001/jama.2018.12163

## Infection and Drug Resistance

Dovepress

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>